Want to join the conversation?
At June 30, 2015, $CME's short and long-term debt rating was maintained by S&P's at A1 and AA- with Stable outlook, and by Moody's Investors Service at P1 and Aa3 with Stable outlook. $CME expects to maintain an investment grade rating given its cash flow generation, ability to pay down debt levels and to refinance existing debt.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?